Vitamin C retards the growth and motility of liver cancer cells huh 7 in wound healing assay

Paper Details

Research Paper 01/10/2017
Views (224) Download (27)
current_issue_feature_image
publication_file

Vitamin C retards the growth and motility of liver cancer cells huh 7 in wound healing assay

Muhammad Imran Raza, Sara Hassan, Wasifa Naushad, Hajra Sadia
Int. J. Biosci.11( 4), 359-364, October 2017.
Certificate: IJB 2017 [Generate Certificate]

Abstract

Vitamin C has long been discussed as having anticancer potential but with little evidence on mechanism of action. Some clinical studies have been performed but with no conclusive results. Researchers have been calling for more studies. The aim of study was to investigate the anti-cancer role of high dose Vitamin C on growth and motility of Liver cancer cells Huh 7 in wound healing Assay. Huh-7 cells were cultured in complete medium (DMEM) at 37oC with 5% CO2. For experimental study design, Huh 7 cells were divided in to two groups as: cells treated with Vitamin C and cell without Vitamin C treatment. To assess the viability of cancer cells upon vitamin C treatment, MTT assay was done. For growth kinetics, cells were plated in a 6 well plate and counted using haematocytometer at different time points. Cancer cell motility was assessed thorough two-dimensional migration wound healing assay. Statistical analysis was done using Graph-pad prism software. Vitamin C treatment inhibits the growth and motility of liver cancer cells. Percentage of wound closure in untreated is high as compared to Vitamin C treated cells which shows Vitamin C significantly retards the growth of Cancer cells (P<0.05). Vitamin C inhibits growth and motility of liver Cancer cells Huh-7 in wound healing assay.

VIEWS 6

Abdel-Hamid NM, Nazmy MH, Mahmoud AW, Fawzy MA, Youssof M. 2011. A survey on herbal management of hepatocellular carcinoma. World Journal of Hepatology 3, 175-83.

Cameron E, Pauling L. 1976. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS 73, 3685-9.

Campbell A, Jack T, Cameron E. 1991. Reticulum Cell Sarcoma: Two Complete ‘Spontaneous’ Regressions, in Response to High-Dose Ascorbic Acid Therapy. Oncology 48, 495-7.

Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. 2002. Vitamin C Suppresses TNFα Induced NFκB Activation by Inhibiting Iκβα Phosphorylation. Biochemistry 41, 12995-13002.

Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. 2008. Pharmacologic doses of ascorbate act as a pro oxidant and decrease growth of aggressive tumor xenografts in mice. PNAS 105, 11105-11109.

Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J. 2014. Intravenous vitamin C and cancer: a systematic review. Integrative Cancer Therapies 13, 280-300.

Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR, Wang Y, Levine M. 1997. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharmaceutical Research 14, 1133-9.

Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J. 2015. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PloS One 10, e0120228.

Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. 2015. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist 20, 210-23.

Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR. 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS 93, 3704-9.

Liang CC, Park AY, Guan JL. 2007. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2, 329-33.

Mc Glynn KA, London WT. 2005. Epidemiology and natural history of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 19, 3-23.

Raza MI, Sikandar A, Sadia A. 2016. Pharmacological Ascorbate triggers apoptotic pathway in Liver cancer cells via up regulation of TNF-α. International Journal of Biosciences 9, 253-258.

Stephenson CM, Levin RD, Spector T, Lis CG. 2013. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 72, 139-46.

Unlu A, Kirca O, Ozdogan M, Nayır E. 2016. High-dose vitamin C and cancer. Journal of Oncological Sciences 1, 10-2.